Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
+$0.37 today
- Market cap
- $1.22B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
Volume 1.39M
Average 1.48M
MLYS Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Mineralys Therapeutics, Inc.NASDAQ: MLYS
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue remains negative
Q2 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $21K.
Context
- Cost of revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $5.25K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How MLYS compares with its peers on the latest reported figures
- MLYS's LTM Jun 2026 cost of revenue of $21K is the 5th highest of the 7 companies compared; the peer median is $224.5K.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $31.49M | +204.6% | +32.7% | 4.8% | |
| LTM Mar 2026 | $1.59M | — | — | 8.0% | |
| LTM Mar 2026 | $238K | +11.2% | -16.1% | 0.7% | |
| LTM Mar 2026 | $211K | — | — | — | |
| LTM Jun 2026 | $21K | — | — | — | |
| LTM Jun 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding MLYS) | $224.5K | +107.9% | +8.3% | 4.8% | |
Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 16.31M | 26.25M | 70.36M | 168.58M | 132.01M |
| Selling, General & Admin | 2.42M | 5.23M | 14.3M | 23.82M | 38.6M |
| Operating Expenses | 18.73M | 31.48M | 84.66M | 192.4M | 170.6M |
| Depreciation & Amortization | 0 | 0 | 0 | 43K | 59K |
| EBITDA | (19.38M) | (28.12M) | (71.9M) | (177.77M) | (154.59M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.73M) | (31.48M) | (84.66M) | (192.4M) | (170.6M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.68M | 12.76M | 14.59M | 15.95M |
| Interest Expense | 27K | 1.68M | 0 | 0 | 0 |
| Other Income / Expenses | (683K) | 1.68M | 12.76M | 14.59M | 15.95M |
| Income Before Tax | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.89) | (5.77) | (1.99) | (3.66) | (2.29) |
| EPS (Diluted) | (3.89) | (5.77) | (1.99) | (3.66) | (2.29) |
| Weighted Avg Shares | 4.98M | 5.17M | 36.19M | 48.54M | 67.66M |
| Weighted Avg Shares (Diluted) | 4.98M | 5.17M | 36.19M | 48.54M | 67.66M |
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
Intrinsic Alpha fair value
Locked
Current Price
$13.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.